As filed with the Securities and Exchange Commission on June 7, 2017

Registration Statement No. 333-

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

PROTEOSTASIS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   20-8436652

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

200 Technology Square, 4th Floor, Cambridge, Massachusetts 02139

(Address of principal executive offices) (Zip Code)

Proteostasis Therapeutics, Inc. 2016 Stock Option and Incentive Plan

Proteostasis Therapeutics, Inc. 2016 Employee Stock Purchase Plan

(Full title of the plan)

Meenu Chhabra

President and Chief Executive Officer

Proteostasis Therapeutics, Inc.

200 Technology Square, 4 th Floor

Cambridge, Massachusetts

(Name and address of agent for service)

(617) 225-0096

(Telephone number, including area code, of agent for service)

With copies to:

Jeff Held

General Counsel

Proteostasis Therapeutics, Inc.

200 Technology Square, 4 th Floor

Cambridge, Massachusetts 02139

  

Mitchell S. Bloom, Esq.

John M. Mutkoski, Esq.

Goodwin Procter LLP

100 Northern Avenue

Boston, Massachusetts 02109

(617) 570-1000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐    Accelerated filer ☐    Smaller reporting company ☐
Non-accelerated filer ☒       Emerging growth company ☒

(Do not check if a smaller reporting company)

     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of securities to be registered   Amount to be
registered (1) 		  Proposed maximum
offering price per
share (2) 		  Proposed maximum
aggregate offering
price (2) 		  Amount of
registration fee (2)

2016 Stock Option and Incentive Plan

Common Stock, $0.001 par value per share

  750,022 shares (3)   $4.385   $3,288,846.47   $381.18

2016 Employee Stock Purchase Plan

Common Stock, $0.001 par value per share

  138,757 shares (4)   $4.385   $608,449.45   $70.52

Total

  888,779 shares           $451.70

 

 

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein.
(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on $4.385, the average of the high and low sale prices of the registrant’s common stock as reported on the Nasdaq Global Market on June 2, 2017.
(3) Represents an automatic increase to the number of shares available for issuance under the registrant’s 2016 Stock Option and Incentive Plan (the “Plan”), effective as of January 1, 2017. Shares available for issuance under the Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on March 31, 2016 (Registration No. 333-210521).
(4) Represents an automatic increase to the number of shares available for issuance under the registrant’s 2016 Employee Stock Purchase Plan (the “ESPP”), effective as of January 1, 2017. Shares available for issuance under the ESPP were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on March 31, 2016 (Registration No. 333-210521).

EXPLANATORY NOTE

This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 (Registration No. 333-210521) of the Registrant is effective. The information contained in the Registrant’s registration statement on Form S-8 (Registration No. 333-210521) is hereby incorporated by reference pursuant to General Instruction E.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8. Exhibits.

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, State of Massachusetts, on June 7, 2017.

 

PROTEOSTASIS THERAPEUTICS, INC.
By:   /s/ Meenu Chhabra
  Meenu Chhabra
  President and Chief Executive Officer

POWER OF ATTORNEY

We, the undersigned officers and directors of Proteostasis Therapeutics, Inc., hereby severally constitute and appoint Meenu Chhabra, our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for her and in her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

/s Meenu Chhabra

Meenu Chhabra

   President, Chief Executive Officer and Director (Principal Executive Officer)   June 7, 2017

/s/ Brett R. Hagen

Brett R. Hagen

   Vice President of Finance, Controller and Assistant Treasurer (Principal Financial and Accounting Officer)   June 7, 2017

/s/ M. James Barrett, Ph.D.

M. James Barrett, Ph.D.

   Chairman of the Board of Directors   June 7, 2017

 

Franklin M. Berger, CFA

   Director   June 7, 2017

/s/ Helen M. Boudreau

Helen M. Boudreau

   Director   June 7, 2017

/s/ Jeffery W. Kelly, Ph.D.

Jeffery W. Kelly, Ph.D.

   Director   June 7, 2017

/s/ Eric B. Rabinowitz

Eric B. Rabinowitz

   Director   June 7, 2017

/s/ Christopher T. Walsh, Ph.D.

Christopher T. Walsh, Ph.D.

   Director   June 7, 2017

INDEX TO EXHIBITS

 

Exhibit No.

  

Description of Exhibit

4.1    Specimen Common Stock Certificate of the Registrant (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-208735)).
4.2    Form of Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-208735)).
4.3    Form of Amended and Restated By-laws (Incorporated by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-208735)).
5.1*    Opinion of Goodwin Procter LLP
23.1*    Consent of PricewaterhouseCoopers LLP
23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1)
24.1*    Power of Attorney (included as part of the signature page to this Registration Statement)
99.1    2016 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-208735)).
99.2    2016 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.15 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-208735)).

 

* Filed herewith.
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Proteostasis Therapeutics Charts.
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Proteostasis Therapeutics Charts.